Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome.
about
Dysfunctional Activation of the Cerebellum in Schizophrenia: A Functional Neuroimaging Meta-AnalysisnAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.Progressive ratio performance following challenge with antipsychotics, amphetamine, or NMDA antagonists in adult rats treated perinatally with phencyclidine.Modulation of midbrain dopamine neurotransmission by serotonin, a versatile interaction between neurotransmitters and significance for antipsychotic drug action.Use of antipsychotics and benzodiazepines in patients with psychiatric emergencies: results of an observational trial.Handwriting movement kinematics for quantifying extrapyramidal side effects in patients treated with atypical antipsychotics.Volumetric changes in the basal ganglia after antipsychotic monotherapy: a systematic review.Novel olanzapine analogues presenting a reduced H1 receptor affinity and retained 5HT2A/D2 binding affinity ratio.A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia.The management of schizophrenia: focus on extended-release quetiapine fumarate.Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: the MIND randomized, placebo-controlled trial.Aripiprazole, a Drug that Displays Partial Agonism and Functional Selectivity.A commentary on "Antipsychotic-induced Parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders".Open label study of the effect of amantadine on weight gain induced by olanzapine.Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study.
P2860
Q27322099-BB17F01E-9E63-4668-AFD9-19B6E73C4323Q30362464-191828E0-CA0F-42C2-8DCC-3C8A40DA8579Q30491416-D7CDD850-70C6-4111-AE19-74002E791346Q30493995-31DECD3D-2E41-4CAA-8B5D-49272964370FQ33353849-39427AC4-43D2-40F1-A22F-C9465CD508B5Q33811763-6BF9DC61-A837-41EE-B167-69718BF8BCB1Q34034400-5C7DD01B-5E09-4FBC-8DC4-BA6A63EF565AQ34314781-3D265252-B504-451C-AF3B-BF1DC2AEB042Q34660425-C7E8AB6C-6FBB-4950-A444-A0EC2DB14B36Q35327044-C696F7B8-89C4-48AA-A5BD-720F988DDC32Q36819213-DD636EC1-30AE-4E70-9D28-F77E09352437Q39244947-89225EFA-A679-4A83-B54C-D7B837CB5C37Q41117908-A8DC95AE-3CA2-4BFE-AD1F-6E08921C1654Q44792435-AACD3564-2812-468E-8D5F-7D8E5FDF8F89Q45257719-C9404469-9B22-40E6-91D3-2E2654668ECD
P2860
Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Extrapyramidal side effects of ...... problem and impact on outcome.
@ast
Extrapyramidal side effects of ...... problem and impact on outcome.
@en
Extrapyramidal side effects of ...... problem and impact on outcome.
@nl
type
label
Extrapyramidal side effects of ...... problem and impact on outcome.
@ast
Extrapyramidal side effects of ...... problem and impact on outcome.
@en
Extrapyramidal side effects of ...... problem and impact on outcome.
@nl
prefLabel
Extrapyramidal side effects of ...... problem and impact on outcome.
@ast
Extrapyramidal side effects of ...... problem and impact on outcome.
@en
Extrapyramidal side effects of ...... problem and impact on outcome.
@nl
P356
P1476
Extrapyramidal side effects of ...... problem and impact on outcome.
@en
P2093
Michael D Jibson
Rajiv Tandon
P2888
P304
P356
10.1023/A:1016811222688
P577
2002-06-01T00:00:00Z
P6179
1085180681